|
First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies. |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - AstraZeneca; Roche/Genentech |
| |
|
Employment - HanX Biopharmaceuticals |
Leadership - HanX Biopharmaceuticals |
Stock and Other Ownership Interests - HanX Biopharmaceuticals |
Patents, Royalties, Other Intellectual Property - HanX Biopharmaceuticals |
| |
|
Employment - HanX Biopharmaceuticals; Tristone Biomed Consulting |
| |
|
Employment - HanX Biopharmaceuticals |
Travel, Accommodations, Expenses - HanX Biopharmaceuticals |
| |
|
No Relationships to Disclose |
| |
|
|
Travel, Accommodations, Expenses - MSD; Roche |
| |
|
No Relationships to Disclose |